Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral
Published . Updated .
On October 2, 2026, Rothschild & Co upgraded their outlook for Abbott Laboratories (NYSE:ABT) (BMV:ABT) from Neutral to Buy.Abbott Laboratories, based in the United States, is a global healthcare company primarily involved in the development, manufacture, and sale of a broad
Directly affected
- ABT Abbott Laboratories
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
A fund of health-care companies
- XBI SPDR S&P Biotech
A fund of biotechnology companies
- UNH UnitedHealth
A large health insurer
- JNJ Johnson & Johnson
A large health-care company
- LLY Eli Lilly
A large drug maker
- PFE Pfizer
A large drug maker
- MKTN FEDERATED HERMES MDT MARKET NEUTRAL ETF
GA selected MKTN as a RELATED security because its canonical security name directly matches this event's themes: neutral. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
On October 2, 2026, Rothschild & Co upgraded their outlook for Abbott Laboratories (NYSE:ABT) (BMV:ABT) from Neutral to Buy.Abbott Laboratories, based in the United States, is a global healthcare company primarily involved in the developme…
Source: Nasdaq Markets
Abbott Laboratories (ABT) since this story, compared with the market
Since the first closing price after “Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral,” Abbott Laboratories (ABT) is +3.91%. The S&P 500 fund (SPY) is -1.08% over the same days, a +4.99% difference versus the market.
Official trades in Abbott Laboratories (ABT) around 2 Oct 2026
- Gilbert Cisneros buy Abbott Laboratories (ABT) ($1,001 - $15,000). That is 14 days before publication, inside 30 days. The filing is listed beside the story “Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral.”
- Rohit Khanna buy Abbott Laboratories (ABT) ($1,001 - $15,000). That is 28 days before publication, inside 30 days. The filing is listed beside the story “Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Abbott Laboratories (ABT)
Companies carried with this story
- ABT Abbott Laboratories
In “Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral,” Abbott Laboratories (ABT) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ABBOTT LABORATORIES in the headline; GA resolved that company to ABT
- MKTN Federated Hermes Mdt Market Neutral Etf
In “Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral,” Federated Hermes Mdt Market Neutral Etf (MKTN) is linked, with no stored direction, medium confidence. Reason on file: GA selected MKTN as a RELATED security because its canonical security name directly matches this event's themes: neutral. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Abbott Laboratories (ABT)
Abbott Laboratories (ABT) is the company in “Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral,” the 2 Oct 2026 this story story.
Abbott Laboratories (ABT) is on the page because The reported development directly names ABBOTT LABORATORIES in the headline; GA resolved that company to ABT
Also listed, Federated Hermes Mdt Market Neutral Etf (MKTN): GA selected MKTN as a RELATED security because its canonical security name directly matches this event's themes: neutral. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Abbott Laboratories (ABT) price range
ABT traded between 95.06 and 105.87 across 20 sessions. The latest close on file is 104.07. MKTN traded between 27.67 and 28.54 across 20 sessions. The latest close on file is 28.49.
How strong the case is around Abbott Laboratories (ABT)
21 out of 100
“Rothschild & Co Upgrades Abbott Laboratories to Buy from Neutral” scores 21 out of 100. The score uses 1 sources, and 2 linked companies.